In addition, endocrine-dependent cancers such as hormone receptor–positive (HR+) breast cancer and androgen receptor–driven (AR+) prostate cancer are closely linked to endocrine signaling despite not arising from endocrine glands (7, 8), which is modulated by estrogen or androgen pathways, and endocrine therapy remains the cornerstone of management. This evidence concerns the gene AR and breast carcinoma.